yi-chu lindec. 7, 2016 1 4th joint conference of taiwan and japan on medical products regulation...

7
衛生福利部食品藥物管理署 Food and Drug Administration, Ministry of Health and Welfare 藥求安全 食在安心 http://www.fda.gov.tw/ Yi-Chu Lin Section Chief, Taiwan FDA Ministry of Health and Welfare Dec. 7, 2016 1 4th Joint Conference of Taiwan and Japan on Medical Products Regulation

Upload: others

Post on 15-Jul-2020

0 views

Category:

Documents


0 download

TRANSCRIPT

Page 1: Yi-Chu LinDec. 7, 2016 1 4th Joint Conference of Taiwan and Japan on Medical Products Regulation 藥求安全 食在安心 2 Working Groups (WG) The collaboration between Taiwan and

衛生福利部食品藥物管理署 Food and Drug Administration, Ministry of Health and Welfare

藥求安全 食在安心

http://www.fda.gov.tw/

Yi-Chu Lin Section Chief, Taiwan FDA

Ministry of Health and Welfare Dec. 7, 2016

1

4th Joint Conference of Taiwan and Japan on Medical Products Regulation

Page 2: Yi-Chu LinDec. 7, 2016 1 4th Joint Conference of Taiwan and Japan on Medical Products Regulation 藥求安全 食在安心 2 Working Groups (WG) The collaboration between Taiwan and

藥求安全 食在安心

2

Working Groups (WG)

The collaboration between Taiwan and Japan since 2013

New Drug Review

Generic Drug Review

GCP Inspection

OTC Issue

Information Sharing

Page 3: Yi-Chu LinDec. 7, 2016 1 4th Joint Conference of Taiwan and Japan on Medical Products Regulation 藥求安全 食在安心 2 Working Groups (WG) The collaboration between Taiwan and

藥求安全 食在安心

3

The Progress of New Drugs WG

Establish the relationship of cooperation

Share the reviewing experiences and develop mutual understanding

The comparison of review report: There are no critical difference in review report between Taiwan and Japan

Amendment of abbreviated review mechanism (TFDA) Case sharing: ethnic differences

2013 2014 2015 2016

Page 4: Yi-Chu LinDec. 7, 2016 1 4th Joint Conference of Taiwan and Japan on Medical Products Regulation 藥求安全 食在安心 2 Working Groups (WG) The collaboration between Taiwan and

藥求安全 食在安心

4

Abbreviated Review Mechanism

Announcement 2011.03.01

Revised

Criteria Advantage

Shorten the review time (180 days)

Accelerate the drug availability and accessibility

NCE with no ethnics difference Approved by two of three

regulators including US FDA, EMA and MHLW/PMDA

2016.07.28

Page 5: Yi-Chu LinDec. 7, 2016 1 4th Joint Conference of Taiwan and Japan on Medical Products Regulation 藥求安全 食在安心 2 Working Groups (WG) The collaboration between Taiwan and

藥求安全 食在安心

5

Case Sharing

Purpose Discussion of drug responsiveness in Asian populations using products approved at different doses in the US, EU, and Japan.

Optimization of drug development in East Asian may be required if there is major ethnic difference resulting in different dose regimen.

For confirmatory trial in some therapeutic categories, such as CV Study, large sample size is required to demonstrate statistically significant efficacy results.

East Asian confirmatory phase III studies , enrolling subjects from Taiwan, Japan ….etc. to facilitate drug development.

Page 6: Yi-Chu LinDec. 7, 2016 1 4th Joint Conference of Taiwan and Japan on Medical Products Regulation 藥求安全 食在安心 2 Working Groups (WG) The collaboration between Taiwan and

藥求安全 食在安心

6

Future Plan

Confidential agreement (CA)

Case sharing & personnel exchange

Joint-review

Page 7: Yi-Chu LinDec. 7, 2016 1 4th Joint Conference of Taiwan and Japan on Medical Products Regulation 藥求安全 食在安心 2 Working Groups (WG) The collaboration between Taiwan and

藥求安全 食在安心

7

For more information Website is at: http://www.fda.gov.tw

Thank You for Your Attention